RemeGen Co., Ltd. (OTCMKTS:REGMF) Sees Significant Decrease in Short Interest

RemeGen Co., Ltd. (OTCMKTS:REGMF) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling 194,690 shares, a decrease of 45.0% from the November 30th total of 354,240 shares. Based on an average trading volume of 94 shares, the short-interest ratio is presently 2,071.2 days. Based on an average trading volume of 94 shares, the short-interest ratio is presently 2,071.2 days.

RemeGen Price Performance

Shares of OTCMKTS REGMF traded down $0.12 during trading hours on Friday, hitting $9.81. 1,000 shares of the company’s stock were exchanged, compared to its average volume of 633. The company’s 50-day moving average price is $10.74 and its 200-day moving average price is $7.77. RemeGen has a 1-year low of $9.81 and a 1-year high of $15.91.

RemeGen Company Profile

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.